Literature DB >> 8090459

193-nm excimer photorefractive keratectomy in high myopia.

N A Sher1, D R Hardten, B Fundingsland, J DeMarchi, E Carpel, D J Doughman, S S Lane, C Ostrov, R Eiferman, J M Frantz.   

Abstract

PURPOSE: To evaluate the refractive results of 193-nm excimer laser photorefractive keratectomy (PRK) performed on 48 highly myopic eyes in a multicenter study.
METHODS: A Visx 2015 or 2000 argon-fluoride excimer laser and a single-zone ablation technique were used. Postoperatively, eyes were treated with topical fluoromethalone for up to 5 months. Most eyes were treated with a 6.0- to 6.2-mm beam diameter after undercorrections and increased regression were noted with a 5.5-mm beam in earlier studies. Forty-eight eyes were treated for myopia, which was between -8.0 and -15.25 diopters (D) (spherical equivalent). The mean preoperative refraction was -11.2 D. Retreatment was performed after 6 to 16 months on 11 eyes for undercorrection. All eyes not retreated were followed for at least 12 months.
RESULTS: At 6 months, follow-up was available on 47 eyes. Of these eyes, 40% and 64% achieved corrections within 1 and 2 D of attempted correction, respectively. At 1 year, 60% of eyes attained 20/40 visual acuity or better uncorrected. Eleven patients (23%) were retreated between 6 to 16 months for undercorrection and/or regression. After retreatment, 47% and 81% of eyes achieved corrections within 1 and 2 D of attempted correction, respectively. At 1 year, 15% of eyes lost two lines of best-corrected visual acuity, and no eyes lost more than two lines. There was slightly more corneal haze seen in this group compared with the haze seen in patients undergoing PRK for low and moderate myopia.
CONCLUSIONS: These data show that excimer PRK can correct high amounts of myopia with reasonable stability after 6 months. Excimer PRK is an effective surgical treatment of severe myopia, but long-term follow-up is still needed to assess the stability of its effect.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8090459     DOI: 10.1016/s0161-6420(94)31135-3

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  9 in total

Review 1.  Excimer laser refractive surgery.

Authors:  E E Manche; J D Carr; W W Haw; P S Hersh
Journal:  West J Med       Date:  1998-07

2.  Excimer laser in-situ keratomileusis (LASIK) under a corneal flap for myopia of 2 to 20 D.

Authors:  T Salah; G O Waring; A el-Maghraby; K Moadel; S B Grimm
Journal:  Trans Am Ophthalmol Soc       Date:  1995

3.  Confocal microscopy reveals persisting stromal changes after myopic photorefractive keratectomy in zero haze corneas.

Authors:  M Böhnke; A Thaer; I Schipper
Journal:  Br J Ophthalmol       Date:  1998-12       Impact factor: 4.638

4.  Analysis of glycosaminoglycans in rabbit cornea after excimer laser keratectomy.

Authors:  T Kato; K Nakayasu; K Ikegami; T Obara; T Kanayama; A Kanai
Journal:  Br J Ophthalmol       Date:  1999-05       Impact factor: 4.638

5.  Optics of conductive keratoplasty: implications for presbyopia management.

Authors:  Peter S Hersh
Journal:  Trans Am Ophthalmol Soc       Date:  2005

Review 6.  Treating myopia with the excimer laser: the present position.

Authors:  D S Gartry
Journal:  BMJ       Date:  1995-04-15

7.  Single-step transepithelial photorefractive keratectomy in high myopia: qualitative and quantitative visual functions.

Authors:  Soheil Adib-Moghaddam; Saeed Soleyman-Jahi; Fatemeh Adili-Aghdam; Samuel Arba Mosquera; Niloofar Hoorshad; Salar Tofighi
Journal:  Int J Ophthalmol       Date:  2017-03-18       Impact factor: 1.779

8.  Excimer laser photorefractive keratectomy for patients with contact lens intolerance caused by dry eye.

Authors:  I Toda; Y Yagi; S Hata; S Itoh; K Tsubota
Journal:  Br J Ophthalmol       Date:  1996-07       Impact factor: 4.638

9.  Contact lens fitting after photorefractive keratectomy.

Authors:  C L Astin; D S Gartry; A D McG Steele
Journal:  Br J Ophthalmol       Date:  1996-07       Impact factor: 4.638

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.